Cargando…

Long-acting preparations of exenatide

Exenatide has been widely used for the treatment of type 2 diabetes mellitus. However, its short plasma half-life of 2.4 hours has limited its clinical application. The exenatide products on the market, twice-daily Byetta™ and once-weekly Bydureon™ (both Amylin Pharmaceuticals, San Diego, CA, USA),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Yunpeng, Wei, Liangming, Ma, Liuqing, Huang, Xiwen, Tao, Anqi, Liu, Zhenguo, Yuan, Weien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771853/ https://www.ncbi.nlm.nih.gov/pubmed/24039406 http://dx.doi.org/10.2147/DDDT.S46970

Ejemplares similares

Novel preparation method for sustained-release PLGA microspheres using water-in-oil-in-hydrophilic-oil-in-water emulsion
por: Hong, Xiaoyun, et al.
Publicado: (2013)

Advances with microRNAs in Parkinson’s disease research
por: Ma, Liuqing, et al.
Publicado: (2013)

Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes
por: Cai, Yunpeng, et al.
Publicado: (2014)

Porous microsphere and its applications
por: Cai, Yunpeng, et al.
Publicado: (2013)

Dissolving and biodegradable microneedle technologies for transdermal sustained delivery of drug and vaccine
por: Hong, Xiaoyun, et al.
Publicado: (2013)

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone
por: Hu, Zhenhua, et al.
Publicado: (2012)

Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats
por: Yang, Xinxin, et al.
Publicado: (2012)

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study
por: Davies, M J, et al.
Publicado: (2009)

Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance
por: Cacciatori, Vittorio, et al.
Publicado: (2017)

Controlled-release and preserved bioactivity of proteins from (self-assembled) core-shell double-walled microspheres
por: Yuan, Weien, et al.
Publicado: (2012)

Surgical wound healing using hemostatic gauze scaffold loaded with nanoparticles containing sustained-release granulocyte colony-stimulating factor
por: Yuan, Weien, et al.
Publicado: (2011)

Oral Delivery of Exenatide via Microspheres Prepared by Cross-Linking of Alginate and Hyaluronate
por: Zhang, Baojie, et al.
Publicado: (2014)

Two cases of type 2 diabetes mellitus in elderly patients successfully treated with monthly exenatide long‐acting release
por: Takenaka, Kenchi, et al.
Publicado: (2019)

pH-sensitive degradable nanoparticles for highly efficient intracellular delivery of exogenous protein
por: Xu, Dan, et al.
Publicado: (2013)

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Lipopolyplex for Therapeutic Gene Delivery and Its Application for the Treatment of Parkinson’s Disease
por: Chen, Wei, et al.
Publicado: (2016)

Autologous erythrocytes delivery of berberine hydrochloride with long-acting effect for hypolipidemia treatment
por: Cheng, Zhongyao, et al.
Publicado: (2020)

Advances with RNA interference in Alzheimer’s disease research
por: Chen, Shun, et al.
Publicado: (2013)

Exenatide: A New Promising Antidiabetic Agent
por: Chakraborti, C. K.
Publicado: (2010)

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
por: Simó, Rafael, et al.
Publicado: (2015)

Exenatide once weekly: clinical outcomes and patient satisfaction
por: Jose, Biju, et al.
Publicado: (2010)

Exenatide Use in the Management of Type 2 Diabetes Mellitus
por: Kyriacou, Angelos, et al.
Publicado: (2010)

Development of dextran nanoparticles for stabilizing delicate proteins
por: Wu, Fei, et al.
Publicado: (2013)

A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes
por: Genovese, Stefano, et al.
Publicado: (2017)

Microneedles As a Delivery System for Gene Therapy
por: Chen, Wei, et al.
Publicado: (2016)

Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications
por: Edwards, Krystal L., et al.
Publicado: (2006)

Exenatide-loaded inside-porous poly(lactic-co-glycolic acid) microspheres as a long-acting drug delivery system with improved release characteristics
por: Zhai, Junqiu, et al.
Publicado: (2020)

Exenatide extended-release; clinical trials, patient preference, and economic considerations
por: Doggrell, Sheila A
Publicado: (2013)

Evolution of Exenatide as a Diabetes Therapeutic
por: Bhavsar, Sunil, et al.
Publicado: (2013)

Metabolic Effects of the Incretin Mimetic Exenatide in the Treatment of Type 2 Diabetes
por: Schnabel, Catherine A, et al.
Publicado: (2006)

A review of exenatide as adjunctive therapy in patients with type 2 diabetes
por: Robles, Gisela I, et al.
Publicado: (2009)

Emerging utility of once-weekly exenatide in patients with type 2 diabetes
por: Goud, Aditya, et al.
Publicado: (2015)

Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
por: Inaishi, Jun, et al.
Publicado: (2022)

Effect of renal impairment on the pharmacokinetics of exenatide
por: Linnebjerg, Helle, et al.
Publicado: (2007)

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017)

Long-acting Preparations in Substance Abuse Management: A Review and Update
por: Hegde, Aditya, et al.
Publicado: (2013)

NMDA receptor regulation of levodopa-induced behavior and changes in striatal G protein-coupled receptor kinase 6 and â-arrestin-1 expression in parkinsonian rats
por: Wu, Na, et al.
Publicado: (2013)

An experimental study of exenatide effects on renal injury in diabetic rats
por: Wang, Xiaodong, et al.
Publicado: (2019)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_p4116lff8s2miq4ecr9nbe0u5q